Yescarta
MarketedA CAR-T therapy for relapsed or refractory diffuse large B-cell lymphoma and related lymphomas, launched in Korea in June 2026 as a non-reimbursed product.
FROM PUBLIC EVENTS · 2026-11-18
Commercial · sales Supplies 12 medicines in Korea and launched a CAR-T therapy there in 2026.
Roles often seen at this stageSales & marketing · Medical & MSL · Regulatory affairs
The Korean unit of Gilead Sciences, founded in 2011, which supplies 12 medicines in Korea across liver disease, HIV, antifungal and oncology.
A CAR-T therapy for relapsed or refractory diffuse large B-cell lymphoma and related lymphomas, launched in Korea in June 2026 as a non-reimbursed product.
An antibody-drug conjugate for triple-negative breast cancer, covered by national health insurance for third-line or later treatment from June 2025.
A chronic hepatitis B treatment supplied in Korea.
Launched the CAR-T therapy Yescarta in Korea as a non-reimbursed product and is pursuing reimbursement listing.
Trodelvy gained national health insurance coverage for third-line or later triple-negative breast cancer.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.